financetom
Business
financetom
/
Business
/
Update: Equifax Q1 Adjusted Earnings, Revenue Rise But Q2, Full-Year Guidance Trails Consensus; Shares Decline Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Equifax Q1 Adjusted Earnings, Revenue Rise But Q2, Full-Year Guidance Trails Consensus; Shares Decline Pre-Bell
Apr 18, 2024 3:39 AM

06:02 AM EDT, 04/18/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Equifax's ( EFX ) shares slumped 9.1% in premarket activity on Thursday after the company's Q1 sales missed guidance, and its forecast for the full year also lagged market expectations.

The company reported Q1 adjusted earnings late Wednesday of $1.50 per diluted share, up from $1.43 a year earlier.

Analysts polled by Capital IQ expected $1.43.

Revenue in the quarter ended March 31 rose to $1.39 billion from $1.3 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.4 billion.

The company expects Q2 adjusted earnings of $1.65 to $1.75 per diluted share on revenue of $1.41 billion to $1.43 billion. Analysts surveyed by Capital IQ expect EPS of $1.87 on revenue of $1.44 billion.

The company expects 2024 adjusted earnings of $7.20 to $7.50 per diluted share on revenue of $5.67 billion to $5.77 billion. Analysts surveyed by Capital IQ expect EPS of $7.63 on revenue of $5.79 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer Raises Outlook on Higher COVID-19 Drug Sales View as Third Quarter Results Beat Street
Pfizer Raises Outlook on Higher COVID-19 Drug Sales View as Third Quarter Results Beat Street
Nov 3, 2024
08:48 AM EDT, 10/29/2024 (MT Newswires) -- Pfizer ( PFE ) lifted its full-year outlook on Tuesday, driven by higher expectations for sales of its COVID-19 drugs, after the pharmaceutical giant swung to higher-than-expected earnings in the third quarter and revenue jumped 31%. The company now expects adjusted earnings in a range of $2.75 to $2.95 for 2024, up from...
Check Point Q3 Earnings: Security Subscriptions Revenue Soars 11.5%, But Margins Slip As Expenses Rise
Check Point Q3 Earnings: Security Subscriptions Revenue Soars 11.5%, But Margins Slip As Expenses Rise
Nov 3, 2024
Check Point Software Technologies Ltd ( CHKP )  reported fiscal third-quarter revenue growth of 7% year-on-year to $635.10 million, marginally missing the analyst consensus estimate of $635.14 million.  The American-Israeli enterprise security solution provider’s adjusted EPS of $2.25 was in line with the analyst consensus estimate. Revenue from Products and licenses grew by 4.1% to $118.9 million, Security subscriptions increased 11.5% year over year to $276.9 million, and Software updates...
IPG Photonics to Acquire Laser Cleaning Services Provider CleanLASER
IPG Photonics to Acquire Laser Cleaning Services Provider CleanLASER
Nov 3, 2024
08:48 AM EDT, 10/29/2024 (MT Newswires) -- IPG Photonics ( IPGP ) said Tuesday it has agreed to acquire laser cleaning services provider Clean-Lasersysteme, known as cleanLASER. Financial terms were not disclosed. The manufacturer of fiber lasers said the acquisition, subject to regulatory approval, is expected to close in Q4. IPG said it plans to provide more information about the...
Ecolab Q3 Adjusted Earnings, Net Sales Rise; 2024 EPS Outlook Updated
Ecolab Q3 Adjusted Earnings, Net Sales Rise; 2024 EPS Outlook Updated
Nov 3, 2024
08:19 AM EDT, 10/29/2024 (MT Newswires) -- Ecolab ( ECL ) reported Q3 adjusted earnings Tuesday of $1.83 per diluted share, up from $1.54 a year earlier. Analysts polled by Capital IQ expected $1.82. Net sales for the quarter ended Sept. 30 were $4 billion, up from $3.96 billion a year earlier. Analysts surveyed by Capital IQ expected $4.03 billion....
Copyright 2023-2026 - www.financetom.com All Rights Reserved